Febuxostat and Cardiovascular Events: A Systematic Review and Meta-Analysis
Background. Febuxostat is approved in the United States for the management of hyperuricemia in patients with gout. In November 2017 the FDA released a warning alert on a possible link between febuxostat and cardiovascular disease (CVD) reported in a single clinical trial. Objective. To conduct a sys...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Hindawi Limited
2019-01-01
|
| Series: | International Journal of Rheumatology |
| Online Access: | http://dx.doi.org/10.1155/2019/1076189 |